Saurashtra News

2019 Anti-infective Drugs Market | North America To Witness Long-Term Growth Outlook For About 47% of Global Market

 Breaking News
  • No posts were found

2019 Anti-infective Drugs Market | North America To Witness Long-Term Growth Outlook For About 47% of Global Market

September 04
15:45 2019
2019 Anti-infective Drugs Market | North America To Witness Long-Term Growth Outlook For About 47% of Global Market

Anti-Infective Drugs Market By Type Of Product (Antibiotics, Antivirals, Antifungals And Others (Including Anthelminthic And Antiprotozoal Drugs)), Opportunities And Strategies – Global Forecast To 2022
Gilead Sciences Was The Largest Company In The Anti-Infective Drugs Market, According To TBRC’s Report (Companies: Gilead Sciences, GlaxoSmithKline, Merck & Co., Teva Pharmaceuticals And Johnson & Johnson)

The global market for anti-infective drugs reached a value of nearly $89 billion in 2018. North America is the largest market for anti-infective drugs manufacturing companies, accounting for around 48% of the global market. The USA is the largest country in terms of value in the anti-infective drugs market.

The anti-infective drugs market consists of sales of branded and generic anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that produce branded or generic anti-infective drugs to treat microbial infections. The anti-infective drugs industry includes establishments that produce antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti-helminthic drugs to kill internal parasites and antiprotozoal agents.

Read More On The Global Anti-Infective Drugs Market Report At:
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anti-Infective Drugs Market Size
The anti-infective drugs market is expected to grow at a growth rate of around 6% to nearly $116 billion by 2022.Growth in the historic period resulted from the rise in incidence rate of infectious diseases, aging population and growth in emerging markets. Going forward, the global economic growth and developments in drug discovery procedures will drive growth of the market. Factors that negatively affected growth in the historic period were patent expiration of drugs, pricing pressures from regulators, and low return on Investment in the anti-infective drugs industry.

The global anti-infective drugs market is relatively concentrated. Players in the market include Gilead Sciences, GlaxoSmithKline, Merck & Co., Teva Pharmaceuticals and Johnson & Johnson.

Gilead was the largest competitor in the anti-infective drugs market in 2017 with around 29% market share. Gilead is an American biopharmaceutical company that discovers, develops and commercializes therapeutics for areas such as cardiovascular and inflammation/respiratory diseases, hematology/oncology, human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection. The company was founded in 1987 and is headquartered in Foster City, California, United States.

Request A Free Sample Of The Global Anti-Infective Drugs Market Report At:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2348&type=smp

Some of the major drivers of the market are:

Economic Growth – The global economy is expected to go through a continued period of steady growth during the forecast period, thus positively impacting the growth of the anti-infective drugs market. Economic growth will result in a rise in income levels, increased access to healthcare facilities and investments in the pharmaceutical industry.

Developments In Drug Discovery Procedures – The anti-infective drugs market is expected to benefit from the latest developments in drug discovery procedures such as stem cells and organ-on-chip (OOC) technologies. OOCs are micro-engineered biometric systems that simulate the activities, mechanics and physiological responses of organ systems.

However, the market is expected to face restraints from several factors such as –

Antimicrobial Resistance – The anti-infective drugs market is expected to be restrained by an increasing number of antimicrobial resistance cases due growing ineffectiveness of conventional anti-infective drugs such as penicillin. Antimicrobial resistance is the final stage of the adaptation process of microorganisms such as bacteria to the environment developing the ability to resist the effects of anti-infective drugs.

Shortage Of Anti-Infective Drugs – The rapid growth in the patient pool and expected shortage of anti-infective drugs, especially antibiotics, are expected to restrain the growth of the anti-infective drugs market in the forecast period. A small number of antibiotics manufacturers with limited outputs cause a shortage of antibiotics in the treatment of bacterial infections when there are multiple cases.

About The Business Research Company

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Media Contact
Company Name: The Business Research Company
Contact Person: Nitin
Email: Send Email
Phone: 08897263534
Address:1st Floor, Anshu Colors Building, Road Number 1 Park View Enclave, Jubilee Hills
City: Hyderabad 500033
State: Telengana
Country: India
Website: https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market